#### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		(11) International Publication Number:	WO 96/20284	
C12P 21/00, C07K 14/415, A61K 38/16, 7/48	A1	(43) International Publication Date:	4 July 1996 (04.07.96)	
(21) International Application Number: PCT/EP	95/050			
(22) International Filing Date: 21 December 1995 (2	21.12.9	CH, CN, CZ, DE, DK, EE, ES, KE, KG, KP, KR, KZ, LK, LR, L MK, MN, MW, MX, NO, NZ, I SG, SI, SK, TJ, TM, TT, UA, U	S, LT, LU, LV, MD, MG, PL, PT, RO, RU, SD, SE,	
(30) Priority Data: MI94A002663 28 December 1994 (28.12.94	<b>4)</b>	patent (AT, BE, CH, DE, DK, ES MC, NL, PT, SE), OAPI patent ( GA, GN, ML, MR, NE, SN, TD, LS, MW, SD, SZ, UG).	FR, GB, GR, IE, IT, LU, BF, BJ, CF, CG, CI, CM,	
(71) Applicant (for all designated States except US): 1 S.P.A. [IT/IT]; Viale Ortles, 12, 1-20139 Milano (I		A		
(72) Inventors; and (75) Inventors/Applicants (for US only): BOMBARDEL [IT/IT]; Viale Ordes, 12, I-20139 Milano (IT). POl Cesare [IT/IT]; Viale Ordes, 12, I-20139 Milano (I	NZON			
(74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevetti Rossini, 8, I-20122 Milano (IT).	uale, V	ia		

(54) Title: HYDROXYPROLINE-RICH PROTEINS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS CONTAINING THEM

#### (57) Abstract

The invention relates to hydroxyproline-rich glycoproteins, which can be obtained by acid alcohol extraction from Taxus spp., Gingko biloba, Lycopersicum esculentum and Daucus carota cell cultures, having the following characteristics: average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis; high solubility in water.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM AT AU BB BE BF BG BJ BY CA CF CG CH CI CM CS CZ DE DK EE ES FI FR GA	Armenia Austria Austria Austria Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Czechoslovakia Czech Republic Germany Denmark Estonia Spain Finland France Gabon	GB GE GN GR HU IE IT JP KE KG KP  KR LI LK LR LT LU LV MC MD MG MI MN MR	United Kingdom Georgia Guinea Greece Hungary Ireland Italy Japan Kenya Kyrgystan Democratic People's Republic of Korea Republic of Korea Kazakhstan Liechtenstein Sri Lanka Liberia Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar Mali Mongolia Mauritania	MW MX NE NL NO NZ PL PT RO RU SSE SG SI SK SN SZ TD TG US US US VN	Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal Romania Russian Federation Sudan Sweden Singapore Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan
---	---	--	--	--	--

# HYDROXYPROLINE-RICH PROTEINS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS CONTAINING THEM

The present invention relates to hydroxyproline-rich glycoproteins which can be obtained from vegetable sources, and to the pharmaceutical and cosmetic use thereof.

- More precisely, the invention relates to hydroxyproline-rich glycoproteins, which can be obtained by acid alcohol extraction from <a href="Taxus spp.">Taxus spp.</a>, <a href="Gingko biloba">Gingko biloba</a>, <a href="Lycopersicum esculentum">Lycopersicum esculentum</a> and <a href="Daucus carota">Daucus carota</a> cell cultures, having the following characteristics:
- 10 average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis;
  - solubility in acid aqueous solutions.

Some glycoproteins of animal origin, such as collagen and proteoglycans, are known to exert a beneficial action on the skin when applied topically as such or incorporated in suitable formulations.

Collagen, which is a glycoprotein rich in proline and hydroxyproline, is especially used as such or combined with other polypeptide bases in the treatment of wrinkles and other unaesthetic blemishes linked to poor skin hydration and elasticity. The animal origin of collage, however, limits its use because of the risks of contamination from viruses and toxins. Though the compounds of vegetable origin do not involve these risks, so far their use in cosmetics has been quite limited: for examples, cosmetic formulations are known which contain raw extracts of such plants as Aloe or

2

even entire minced vegetables such as avocado.

Vegetable glycoproteins, called extensines, that are produced from vegetable cells in the proliferation stage and have a similar structure to animal collagen, are known. EP-A-0 533 4078 discloses the cosmetic use of extensines having an average molecular weight above 100,000 Daltons. However, the methods for the extraction of extensines described to date, which involve the extraction of vegetable materials of various origin by means of aqueous saline solutions, followed by purification with strong acids such as trichloroacetic acid, do not allow to obtain suitable products for cosmetics, due to problems concerning solubility, stability, repeatability and consistency of chemical-physical characteristics.

It has now been found that it is possible to obtain hydroxyproline-rich glycoproteins, structurally similar to the above described extensines but with a lower molecular weight and a higher solubility in acid aqueous solutions, by means of a procedure comprising the in vitro culture of cells of selected plants and the extraction, with acid alcoholic solutions, of the cells grown in a suitable medium.

The glycoproteins obtainable according to the 25 invention have hydrating, film-forming, toning and cicatrizant properties higher than those of collagen. The glycoproteins of this invention can therefore be employed in cosmetic or dermatologic formulations for treatment of dry skin, psoriasis, ichtyosis, 30 dandruff, keratosis, wrinkles, acne, inflammatory dermatosis, ageing of the skin and all the

5

10

15

3

other applications for which the use of animal collagen has been proposed.

The aqueous solutions of the glycoproteins of the invention remain stable without any polymerisation of the glycoproteins leading to the formation of insoluble products. In addition, the viscosity of these solutions is particularly high and not dependent on the concentrations; 0.1% concentrations surprisingly have the same film-forming and hydrating power equal as 1% collagen or 5% vegetable albumin solutions.

The vegetable material to be extracted is obtained from fermenter cultures of Taxus spp., Gingko biloba, Lycopersicum esculentum and Daucus carota cells. The use of cells from the species Taxus spp., Gingko biloba and Lycopersicum esculentum is particularly preferred. The cell culture techniques are conventional and include the suspension culture starting from callus cultures from various parts of the plants such as leaves, bark, roots, trunk or seeds, as described by Dobbs and Roberts, Experiments in Plant Tissue Culture, 2nd ed. Cambridge University Press, New York, 1985.

The vegetable tissue of the callus, following sterilisation and optional addition of antibacterials, is typically used for the inoculum of suitable liquid culture media as described in the above mentioned Manual by Dobbs and Roberts. A particularly suitable medium for this invention is the Murashige and Skoog medium. The addition of specific additives such as proline, reducing agents, ethylene or compounds capable of releasing ethylene such as Ethephon or L-aminocyclopropanecarboxylic acid, may be suitable to

5

10

15

20

25

4

productivity in the desired glycoproteins.

The use of naphthylacetic acid as the as auxin, 6-(Y,Y-dimethylamino)-purine as the cytokinin, vitamins and 3% saccharose as the carbon source is preferred. The addition of vitamin C may be suitable, depending on the material chosen, to prevent the final product from browning.

The fermentation time may vary from 3 to 12 days and is preferably between 5 and 6 days. Once the fermentation has been completed, the culture medium is centrifuged and the cellular mass is extracted by means of alcohols, preferably ethanol, in the presence of diluted mineral acids, preferably hydrochloric or sulphuric acid. This procedure inactivates some enzymes that may jeopardise the stability of the glycoproteins of the invention, specifically of polyphenoloxidase and tyrosine oxidase which favour the polymerization of glycoproteins with the consequent formation of insoluble products.

20 The alcohol extraction in the presence of mineral acids allows the complete extraction of glycoproteins and has proved to be extremely selective to this end. Other water-mixable alcohols, such methanol or isopropanol, can be used besides ethanol. The resulting hydroalcoholic extracts are neutralised 25 and then concentrated and heated to a temperature of 70°C to 100°C, preferably around 80°C, up to complete precipitation of the denatured proteins. The suspension is then clarified by concentration and the fluid is subjected to fractional ultrafiltration to remove high 30 and low molecular weight substances. Ultrafiltration is

5

10

5

performed by means of polysulphonic membranes having cut-off of 10,000 Daltons to 40,000 Daltons, such as Centricon<sup>R</sup> or Romicon<sup>R</sup>, whose fibres may be hollow or, alternatively, coiled. The resulting filtered product is electrodialysed to remove undesired substances such as salts and low molecular weight sugars. After filtration and dialysis, the resulting solution can be used as such in cosmetic or pharmaceutical preparations or it can be concentrated to a lower volume and then lyophilised or atomised.

The analytical characterization of the products of the invention was carried out by gel permeation using a high-pressure liquid chromatograph consisting of Waters pump unit and provided with a Ultrahydrogel Linear Waters R column battery 30 cm  $\times$  0.5 cm and Waters UV absorption detector, model 484. An aqueous solution containing 0.067 M monopotassium phosphate, 0.1 M NaCl and 6 x  $10^{-4}$  M NaN<sub>3</sub> was used as the eluent. glycoprotein samples to be analysed are dissolved in the same eluent solution (3 mg/10 ml) and scalar amounts of substance as well as the reference substances selected as molecular weights between Cytochrome (12,400 Daltons) and dextran blue (2,000,000 Daltons); alternatively or simultaneously the products or their intermediates can be determined by electrophoresis on 12.5% polyacrylamide gel and 4% stacking gel. The samples to be analysed are dissolved in buffer containing SDS and 0.1% mercaptoethanol while depositing quantities between 100 mg and 300 mg. The migration is carried out at a constant current at 20 mA for 4 hours. A gauging curve is drawn with 5 standard weights (7kD,

5

10

15

20

25

6

14kD, 24kD, 54kD and 66kD). Weights of 22.5kD and 25kD are calculated from this gauging curve for the two main bands and weights of 31kD and 34kD are calculated for the less intense bands. The procedures described here allow mixtures of products with comparable molecular weights and comparable amino acid compositions to be obtained from the various cell explants starting from different plants. The results of the amino acid analysis of glycoproteins extracted from Ginkgo biloba cells are shown below as an example.

	Amino acid	Peak area %			
	Asp	4.399			
	Glu	4.328			
	Нур	17.505			
15	Ser	7.065			
	Gly	6.056			
	Hys	1.782			
	Arg	2.471			
	Thr	4.739			
20	Pro	10.036			
	Ala	8.2			
	Tyr	2.388			
	Val	6.162			
	Met	1.154			
25	Ile	2.479			
	Leu	5.525			
	Phe	1.862			
	Lys	14.254			

The above data refer to the percentage of the total

amount of amino acids present in the glycoprotein

mixture. The sugars in the mixture are arabinose and

5

7

galactose. The ratio of amino acids to sugars is on average 2:1 for the various products.

As mentioned above, the products according to the invention can be used both in the pharmaceutical and cosmetic fields. For the pharmaceutical field, the product may be incorporated in gels or ointments or applied on medicated gauzes for specific treatment of burns or wounds. In this case the product is usually subjected to sterilisation or sterile filtrations and lyophilised.

The cosmetic and dermatologic preparations of the invention can be prepared according to traditional methods. Examples of administration forms include aqueous sprays, lotions, solutions, emulsions, gels, ointments and creams.

The cosmetic and dermatologic preparations of the inventions can contain hydroxyproline-rich glycoproteins in weight percentages of about 0.01% to about 50%, preferably from 0.05% to 5%, as well as conventional excipients. Given the high stability of the glycoproteins of this invention, pharmaceutical and cosmetic preparations containing above 50% of soluble hydroxyproline-rich glycoproteins can be obtained.

The glycoproteins of the invention can be added to pharmaceutical and cosmetic preparations as such or microencapsulated so as to provide a long-term hydrating action. The microcapsules can be either hydrophilic or lipophilic. The preparations of the invention may include other active principles having complementary or useful activity for the desired aims.

The invention is further illustrated by the

5

10

15

20

25

8

following examples.

#### Example 1

# Preparation of the callus and liquid culture of Ginkgo biloba for the production of glycoproteins

5 An explant of young leaves of Ginkgo biloba is prepared by washing the leaves in a 0.1% Tween 80(R) solution. The laminae are sectioned in fractions of about 0.5 cm and pre-sterilised for 1 minute with 75% ethanol. The sterilisation is then completed with a 2% 10 sodium hypochlorite solution and triple washing of the explant in sterile water. The resulting explants are transferred to a Petri dish in Murashige & Skoog medium containing 3% saccharose with the addition of Lynsmeyer Skoog vitamins and hormones such dichlorophenoxyacetic acid and naphthylacetic acid. The 15 products are incubated in the dark at 23°C for 20 days. At the end of this period, friable calli are obtained which grow easily and are moved in continuous rows by means of subcultures in the same conditions, as they can be used for propagation in a liquid medium. These calli 20 are used to inoculate Erlenmeyer flasks containing 200 ml of Murashige & Skoog medium, with the addition of naphthylacetic acid and 6  $(\gamma, \gamma$ -dimethylamino)-purine, Lynsmeyer & Skoog vitamins and 3% saccharose as a source of carbon. The flasks are incubated with stirring in 25 continuous light for 4 days, after which the cell biomass is harvested for the extraction of glycoproteins.

#### Example 2

30 Preparation of glycoproteins from Ginkgo biloba cells

5 liters of the culture obtained according to

9

Example 1 are low-speed centrifuged and the harvested cells (1.5 kg of fresh weight) are extracted with 1.5 l 70% ethanol containing 1% sulphuric acid. extraction is repeated twice thereby quantitatively recovering the basic glycoproteins. neutralisation, the extracts are filtered to remove any turbidity and concentrated under vacuum at 50°C until ethanol is completely removed. The aqueous concentrate is heated at 85°C for 30 minutes and centrifuged again to remove the precipitate, which is discarded. resulting clear solution is ultrafiltered by means of a  ${\tt Centricon}^{\tt R}$  membrane with cut-off 40,000 Dalton limit to exclude the higher molecular weights.

The filtered product is then ultrafiltered using a hollow-fibre membrane with cut-off 10,000 Dalton to remove non-glycoprotein, low-molecular weight substances. The filtrate is then subjected to dialysis and concentrated to 1% of solid residue. 1.5 litres of a slightly viscous product is obtained, which may be used as such in cosmetic formulations. At the electrophoresis analysis, the product contained 6 bands, 4 of which had molecular weights of 16,000, 22,000, 33,000 and 36,000 Daltons.

#### Example 3

25 <u>Preparation of glycoproteins from Lycopersicum</u> esculentum

Following the procedure of Example 1, a cell mass from sterile buds of Lycopersicum esculentum is prepared in a 14-liter fermenter containing 10 litres of Murashige & Skoog medium added with naphthylacetic acid and 6 ( $\Upsilon$ , $\Upsilon$ -dimethylamino)-purine, Lynsmeyer & Skoog

30

5

10

15

10

vitamins and 3% saccharose as a carbon source. The fermentation is carried on for 5 days at 23°C while stirring at 150 rpm in the presence of yeast extract at 0.05% concentration and with an approximately 70% 5 concentration of dissolved oxygen. At the end of the fermentation the broth is gathered and micro-filtered through a  $0.2~\mu m$  ceramic membrane to concentrate the cells. Some isopropanol containing 0.5% hydrochloric acid is added to the cell paste thus obtained and the method described in Example 2 is applied to the extracts. 3.5 litres of a solution are obtained with 0.5% dry residue. The analysis of the lyophilised solutions gave a content of 10% proline and 31% hydroxyproline, respectively.

15 Example 4

#### Cosmetic formulation

100 g of O/W emulsion contain: SOLUTION OF THE EXAMPLE 2 OR 3

10.0 g Acetylated lanolin alcohol PEG-10 2.0 g 20 Cetyl-stearyl alcohol 1.5 g Cetyl palmitate 2.0 g Stearic acid 7.0 g Octyl octanoate 7.5 g Potassium cetyl phosphate 0.5 q25 Preservatives q.s.

#### Example 5

q.s.

q.s. to 100 q

#### Cosmetic formulation

Fragrance

Purified water

30 100 g of O/W emulsion contain: SOLUTION OF THE EXAMPLE 2 OR 3 10.0 g

WO 96/20284

#### PCT/EP95/05084

	Cetyl stearyl glucoside	5.0 g
	Jojoba oil	10.0 g
	Isopropyl myristate	8.0 g
	Dimethicone	0.5 g
5	Antioxidant	q.s.
	Preservatives	q.s.
	Fragrance	q.s.
	Purified water	q.s. to 100 g

÷,

5

15

25

12

#### **CLAIMS**

- 1. Hydroxyproline-rich glycoproteins, obtainable by acid-alcohol extraction from <u>Taxus spp.</u>, <u>Gingko biloba</u>. <u>Lycopersicum esculentum</u> and <u>Daucus carota</u> cell cultures, having the following characteristics:
- average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis;
- 10 high solubility in water.
  - 2. A process for the preparation of the glycoproteins of Claim 1, which process comprises:
  - a) culture of <u>Taxus spp.</u>, <u>Gingko biloba</u>. <u>Lycopersicum</u>

    <u>esculentum</u> and <u>Daucus carota</u> cells in a liquid

    medium for a time from 3 to 12 days;
  - b) extraction of the cell mass from with water-mixable alcohols in the presence of diluted mineral acids;
  - c) neutralisation, concentration and heating of the extracts at temperatures between 70°C and 100°C;
- 20 d) centrifugation, fractional ultrafiltration and dialysis.
  - 3. Cosmetic and pharmaceutical preparations containing the glycoproteins of Claim 1 as active principle, having hydrating, film-forming, toning and cicatrizant properties.
  - 4. Preparations according to Claim 3 in the form of aqueous sprays, lotions, solutions, emulsions, gels, ointments, creams, and medicated gauzes.

## INTERNATIONAL SEARCH REPORT

Inter onal Application No PCT/EP 95/05084

CLASS		rei/Er 3	
A. CLASS IPC 6	SIFICATION OF SUBJECT MATTER C12P21/00 C07K14/415 A61K38	3/16 A61K7/48	
According	to International Patent Classification (IPC) or to both national cla	assification and IPC	
B. FIELD	S SEARCHED		
IPC 6	documentation searched (classification system followed by classifi A61K C07K		
	ation searched other than minimum documentation to the extent th		
Electronic o	data base consulted during the international search (name of data	base and, where practical, search terms used)	
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claum No.
A	EP,A,O 533 408 (REVLON, INC.) 24 1993 cited in the application see page 3, line 3 - page 5, lin		1-4
A	PLANT PHYSIOL., vol. 84, 1987, pages 820-825, XP000569867 JOEL P. STAFSTROM ET AL.: "A SE EXTENSIN-LIKE HYDROXYPROLINE-RIC GLYCOPROTEIN FROM CARROT CELL WA	CH I	
Furth	ner documents are listed in the continuation of box C.		
<u> </u>		X Patent family members are listed in	n annex.
'A' documer consider 'E' earlier di filing di 'L' documer which is citation 'O' documer other m	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	"T" later document published after the inter- or priority date and not in conflict wit- cited to understand the principle or the invention  "X" document of particular relevance; the o- cannot be considered novel or cannot involve an inventive step when the doc- "Y" document of particular relevance; the o- cannot be considered to involve an inv- document is combined with one or mo- ments, such combination being obvious in the art.  "A" document member of the same material.	th the application but early underlying the claimed invention be considered to cument is taken alone claimed invention ventive step when the are other such docusts to a person skilled
	ctual completion of the international search	'&' document member of the same patent if  Date of mailing of the international sea	
	May 1996	1 0. 05, 96	•
Name and ma	ailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Ripwijk  Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+ 31-70) 340-3016	Authorized officer  Rempp, G	

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

ormation on patent family members

PCT/FP 95/05084

			PCI/EP	95/05084	
Patent document cited in search report	Publication date	Patent memi	family ber(s)	Publication date	
EP-A-533408	24-03-93	JP-A- US-A- ZA-A-	6107517 5443855 9207075	19-04-94 22-08-95 16-03-94	
	·				

Form PCT/ISA/210 (petent family enest) (July 1992)